The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Shukui Qin
No Relationships to Disclose
 
Lorenzo Antonuzzo
Honoraria - Amgen; AstraZeneca; Novartis; Roche
Consulting or Advisory Role - Merck Serono
 
David Tougeron
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; BMS; MSD; Novartis; Pierre Fabre; Sanofi; SERVIER; Takeda
Research Funding - BTG (Inst); Gilead Sciences (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Choong-kun Lee
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Roche; SERVIER
Speakers' Bureau - Boryung Pharmaceuticals; Celgene/Bristol-Myers Squibb; Handok; Novartis; Sanofi
Research Funding - Boryung Pharmaceuticals (Inst); GC Biopharma (Inst); Lunit (Inst); Ono Pharmaceutical (Inst)
 
Benjamin Tan
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Tvardi Therapeutics (Inst); TYME (Inst)
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Julie Wang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Hung-Ying Lin
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Young Lee
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Patricia McCoon
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Juan Valle
Consulting or Advisory Role - AstraZeneca; Cogent Biosciences (Inst); Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals (Inst); Oncosil (Inst); Owkin (Inst); Redx Pharma (Inst); SERVIER; Taiho Oncology